Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap [Seeking Alpha]
Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data [Yahoo! Finance]
Public companies account for 34% of Journey Medical Corporation's (NASDAQ:DERM) ownership, while institutions account for 33% [Yahoo! Finance]
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology